Cancer Clinical Trial
Official title:
The Effectiveness of Whole-body 18F-NaF PET in Detecting Metastatic Bone Lesion for Patients With Cancer: A Comparison Study With 99mTc-MDP Bone Scintigraphy.
18F ion is a positron emitting bone radiopharmaceuticals. The skeletal uptake of 18F relies
on the exchange of hydroxyl ions in the hydroxyapatit crystal which is an indicator of bone
metabolic activity (8). It has good soft tissue clearance and high affinity of to the bone
matrix. It is able to perform a highly sensitive whole-body screening for bone metastases
using a high resolution PET scanner. Therefore, we conduct a prospective study to evaluate
the accuracy and clinical value of 18F PET in staging bone metastases by
1. Comparing the sensitivity of 18F-NaF PET with that of 99mTc-MDP scintigraphy;
2. Determining the clinical impact of PET results on subsequent patient management.
Skeletal metastases are the most common cause of morbidity and mortality in patients with
malignancy, especially in patients with breast cancer, lung cancer, prostate cancer and head
& neck cancer. In patients with lung cancer, bone metastases are present in 20-30% of
patient at initial diagnosis (1-2). Accuracy staging bone metastases can lead to
modification of following treatment and evaluation of prognosis.
The planar whole-body 99mTc-methylene diphosphonate (MDP) radionuclide bone scintigraphy is
the most widely used technique in detecting metastatic bone lesions at present. Abnormal
tracer accumulation may occur at any skeletal site with an elevated rate of bone turnover.
However, conventional planar bone scintigraphy was reported to be less sensitive than MRI in
detecting spinal metastases (3-7).
18F ion is a positron emitting bone radiopharmaceuticals. The skeletal uptake of 18F relies
on the exchange of hydroxyl ions in the hydroxyapatit crystal which is an indicator of bone
metabolic activity (8). It has good soft tissue clearance and high affinity of to the bone
matrix. It is able to perform a highly sensitive whole-body screening for bone metastases
using a high resolution PET scanner.
To the best of our knowledge, there are only limited studies evaluating the clinical
utilization of 18F-NaF PET for detection of bone metastases (10-12). Therefore, we would
like to conduct a prospective study to evaluate the accuracy and clinical value of 18F PET
in staging bone metastases by
1. Comparing the sensitivity of 18F-NaF PET with that of 99mTc-MDP scintigraphy;
2. Determining the clinical impact of PET results on subsequent patient management.
99mTc-MDP scintigraphy and 18F PET will be performed in 2 weeks for all patients.
Interpretation of 99mTc-MDP scintigraphy and 18F PET will be performed following the
criteria described by Crasnow et all (13). The accuracy of 99mTc-MDP scintigraphy and 18F
PET detection of bone metastases for each patient will be determined by the
histopathological results, MRI results, or other clinical evidences afterward.
;
Observational Model: Case Control, Time Perspective: Prospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05346796 -
Survivorship Plan HEalth REcord (SPHERE) Implementation Trial
|
N/A | |
| Recruiting |
NCT05094804 -
A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
|
Phase 1/Phase 2 | |
| Completed |
NCT04867850 -
Effect of Behavioral Nudges on Serious Illness Conversation Documentation
|
N/A | |
| Enrolling by invitation |
NCT04086251 -
Remote Electronic Patient Monitoring in Oncology Patients
|
N/A | |
| Completed |
NCT01285037 -
A Study of LY2801653 in Advanced Cancer
|
Phase 1 | |
| Completed |
NCT00680992 -
Study of Denosumab in Subjects With Giant Cell Tumor of Bone
|
Phase 2 | |
| Completed |
NCT00062842 -
Study of Irinotecan on a Weekly Schedule in Children
|
Phase 1 | |
| Active, not recruiting |
NCT04548063 -
Consent Forms in Cancer Research: Examining the Effect of Length on Readability
|
N/A | |
| Completed |
NCT04337203 -
Shared Healthcare Actions and Reflections Electronic Systems in Survivorship
|
N/A | |
| Recruiting |
NCT04349293 -
Ex-vivo Evaluation of the Reactivity of the Immune Infiltrate of Cancers to Treatments With Monoclonal Antibodies Targeting the Immunomodulatory Pathways
|
N/A | |
| Terminated |
NCT02866851 -
Feasibility Study of Monitoring by Web-application on Cytopenia Related to Chemotherapy
|
N/A | |
| Active, not recruiting |
NCT05304988 -
Development and Validation of the EFT for Adolescents With Cancer
|
||
| Completed |
NCT04448041 -
CRANE Feasibility Study: Nutritional Intervention for Patients Undergoing Cancer Surgery in Low- and Middle-Income Countries
|
||
| Completed |
NCT00340522 -
Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development
|
||
| Recruiting |
NCT04843891 -
Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis.
|
Phase 1 | |
| Active, not recruiting |
NCT03844048 -
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
|
Phase 3 | |
| Completed |
NCT03167372 -
Pilot Comparison of N-of-1 Trials of Light Therapy
|
N/A | |
| Completed |
NCT03109041 -
Initial Feasibility Study to Treat Resectable Pancreatic Cancer With a Planar LDR Source
|
Phase 1 | |
| Terminated |
NCT01441115 -
ECI301 and Radiation for Advanced or Metastatic Cancer
|
Phase 1 | |
| Recruiting |
NCT06206785 -
Resting Energy Expenditure in Palliative Cancer Patients
|